$0.336
-0.005 (-1.41%)At close
CTSO News
CTSO Events
CytoSorbents Reports Q1 Revenue of $8.9M
Reports Q1 revenue $8.9M vs. $8.7M last year. "First quarter sales were $8.9 million, driven by 13% growth in our direct sales territories outside of Germany," stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents Corporation. "Our Germany sales team also performed well, achieving sales slightly below last year, but with a smaller and more focused team - reflecting new leadership, sales execution, account targeting, productivity, and customer engagement. Given the importance of the German market, we plan to selectively expand our commercial team to improve account coverage and drive growth opportunities in both critical care and cardiac surgery."
CytoSorbents Q4 Revenue Reaches $9.23M
Reports Q4 revenue $9.23M vs. $9.15M last year. "2025 was a transitional year for our business as we made good progress in four key objectives," stated Dr. Phillip Chan, CEO of CytoSorbents. "We ended the year with positive clinical and commercial momentum for 2026, with a lower cost structure and improved balance sheet to support our growth. Additionally, we continue to make progress with the FDA to align on the content and timing of a new De Novo submission for DrugSorb-ATR and look forward to providing further updates in the future."
Fourth Quarter Gross Margin Expected to Reach 73%-75%
Fourth quarter gross margin is expected to be in the range of 73%-75%, compared to 71% in the fourth quarter of 2024, and 70% in the third quarter of 2025.
Full-Year Gross Margin Expected at Approximately 72%
Full-year gross margin is expected to be approximately 72%, compared to 71% for full-year 2024.
CytoSorbents Launches Program to Reduce Workforce and Costs
CytoSorbents announced the implementation of a strategic Workforce and cost reduction plan to further reduce costs, optimize operations, and accelerate the path to cash-flow profitability. This initiative follows a comprehensive internal review of its cost structure and operating model. As part of the strategic plan, CytoSorbents reduced its workforce by approximately 10%, reduced and realigned production and operating expenses, and now expects to reach operating cash flow break-even in Q1 2026. The company expects to record a charge of up to $900K that will include severance and other charges related to the restructuring. The estimated costs that the company expects to incur, and the timing thereof, are subject to a number of assumptions, and actual amounts may differ materially.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.